Edges in Network
| Network | GSE5851_top8000 - GSE5851 - SiGN-BN NNSR |
| Network Description | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| Node | LAPTM5 |
| Upstream (Parents) |
|---|
| (<<) CD53 → LAPTM5 |
| (<<) TYROBP → LAPTM5 |
| (<<) CD86 → LAPTM5 |
| Downstream (Children) |
|---|
| LAPTM5 → CD53 (>>) |
| LAPTM5 → EMP3 (>>) |
| LAPTM5 → DFNA5 (>>) |
| LAPTM5 → LILRB4 (>>) |
| LAPTM5 → SYT11 (>>) |
| LAPTM5 → CCL18 (>>) |
| LAPTM5 → CD84 (>>) |
| LAPTM5 → BCAT1 (>>) |
| LAPTM5 → TUBA8 (>>) |
| LAPTM5 → ACP5 (>>) |
| LAPTM5 → C19orf73 (>>) |
| LAPTM5 → CD37 (>>) |
| LAPTM5 → LILRB3 (>>) |
| LAPTM5 → RASSF4 (>>) |
| LAPTM5 → TIMP2 (>>) |
| LAPTM5 → GPNMB (>>) |
| LAPTM5 → ST8SIA4 (>>) |
| LAPTM5 → ACACA (>>) |
| LAPTM5 → VIM (>>) |
| LAPTM5 → FCGR1B (>>) |
| LAPTM5 → ZEB2 (>>) |
| LAPTM5 → IFI30 (>>) |
| LAPTM5 → FPR3 (>>) |
| LAPTM5 → GLIPR1 (>>) |
